Cargando…
Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID‐19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such pa...
Autores principales: | Al Bishawi, Ahmad, Abdel Hadi, Hamad, Elmekaty, Eman, Al Samawi, Musaed, Nair, Arun, Abou Kamar, Mohammed, Al Maslamani, Muna, Abdelmajid, Alaaeldin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867201/ https://www.ncbi.nlm.nih.gov/pubmed/35228879 http://dx.doi.org/10.1002/ccr3.5467 |
Ejemplares similares
-
Remdesivir therapy causing bradycardia in COVID-19 patients: Two case reports
por: Abdelmajid, Alaaeldin, et al.
Publicado: (2021) -
Evaluation of anakinra in the management of patients with COVID-19 infection: A randomized clinical trial
por: Elmekaty, Eman Zeyad I., et al.
Publicado: (2023) -
Dilemma of Tocilizumab therapy for a patient with critical COVID‐19 disease and neutropenia: Case report and review of the literature
por: Al Bishawi, Ahmad, et al.
Publicado: (2022) -
Remdesivir for patients with Coronavirus disease 2019 pneumonia requiring high oxygen support
por: Alibrahim, Rim S., et al.
Publicado: (2022) -
Otosyphilis: A rare case of reversible hearing loss in a young man with secondary syphilis
por: Sarsak, Enas W., et al.
Publicado: (2022)